The coding exons of DUS3-like and the flanking splice
junctions were screened for mutations by direct sequencing. The
following primers were used: exon 1, 5′-CGCTTTGTAATTGGTGCAGCTC-3′ and
5′-CCAGCGTGGAGAGCC-AGCTG-3′ (PCR product, 416 bp); exon 2,
5′- GCTGCTCTGGACTCACTCAAG-3′ and
5′-CCTGTCTGCCACCCTTCT-CC-3′ (PCR product, 425 bp); exon 3,
5′-GTCTTCCCCAACAACCTGGC-3′ and 5′-CAAATTCCAGGCACCCTGTTC-3′
(PCR product, 319 bp); and exon 4, 5′-GCCCCATGTCACCCTTTCCC-3′
and 5′-CCT-ATCTCCAGCTGGGAGCC-3′ (PCR product, 343 bp). Reactions
were performed in a 50-μl volume with 50 ng of genomic DNA; 20 pmol
of each primer; 200 μM each dATP, dCTP, dGTP, dTTP; 10 mM Tris-HCl
(pH 8.3); 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin
and 1 U Taq DNA polymerase (Gibco BRL). After the initial
denaturation step at 96°C for 3 minutes, the samples were processed
through 35 cycles of 92°C for 30 seconds, 55°C for 30 seconds, and
72°C for 30 seconds. A final extension step was performed at 72°C
for 10 minutes. After amplification, PCR products were processed using
a PCR purification kit (Qiaquick; Qiagen, Valencia, CA) according to
the manufacturer’s instructions. The PCR product was eluted into 30μ
l of 10 mM Tris (pH 8.5), and 5 μl of this purified product was
used in a sequencing reaction. Both the forward and reverse strands of
the PCR products were directly sequenced (ABI 377 sequencer, using the
ABI Prism BigDye Terminator cycle sequencing ready-reaction kit; PE
Applied Biosystems, Foster City, CA). Sequencing reactions were set up
according to the manufacturer’s instructions, using either the forward
or reverse primers detailed earlier.